ReviewJournal of translational medicine2025
Decoding the mechanisms behind second primary cancers.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of developing a second primary cancer following a renal cell carcinoma: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management.Human vaccines & immunotherapeutics · 2026Review
- Article
- From Leukemia to Solid Tumors, Successful Multidisciplinary Management of Three Distinct Primary Cancers in a Single Patient: A Case Report.Clinical case reports · 2026Article
- Integrative proteomics and metabolomics advance early cancer detection and targeted therapy with emerging technologies and clinical applications.Discover oncology · 2026Review
- Impact of prior cancer history on survival in patients with adenocarcinoma of esophagogastric junction: a retrospective cohort study using SEER database.Translational cancer research · 2026Article
- Multiple Primary Cancer Incidence by County-Level Smoking Prevalence among U.S. Cancer Survivors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Distribution analysis of gynecological carcinomas with concurrent second primary carcinomas.Frontiers in oncology · 2026Article
- A study on the temporal patterns, anatomical distribution, and influencing factors of radiation therapy-associated second primary cancers in gynecological malignancies.Frontiers in oncology · 2026Article
- Deciphering the Risk of Developing Lung Cancer after the Diagnosis of Gastric Cancer with Genetic Evidence: A European and East Asian Populations-Based Mendelian Randomization Analysis.Cancer research and treatment · 2026Article
- Synchronous uterine leiomyosarcoma and pulmonary adenocarcinoma in a meerkat (Suricata suricatta): a case report.BMC veterinary research · 2025Article
- Second Cancer Incidence and Cause-Specific Mortality in Primary Gastrointestinal Non-Hodgkin Lymphoma Survivors: A Population-Based Cohort Study.Cancer medicine · 2025Article
- Longitudinal variability of CT imaging features for predicting pulmonary nodule invasiveness: A multicenter study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Multiomics elucidation of surrounding AT2 cells impeding tertiary lymphoid structures function in neoadjuvant chemoimmunotherapy response of multiple primary lung cancers.Journal for immunotherapy of cancer · 2025Article
- Comparative Analysis of Primary and Second Primary Multiple Myeloma: A Propensity Score-Matched Study.Clinical Medicine Insights. Oncology · 2025Article
- Impact of secondary hematologic malignancies on prognosis of Hodgkin's lymphoma survivors.Frontiers in oncology · 2025Article
- Preparing for the Era of Multiple Primary Cancers: A Prevention-Centered Model for Survivorship Medicine.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Second Primary Cancers (SPCs) are defined as cancers that develop either simultaneously or metachronously in the same individual who has been diagnosed with and survived one primary cancer. SPCs exhibit a high incidence rate and represent the primary cause of mortality among survivors of first primary cancers. There is growing concern about the dangers of SPCs. This review summarizes recent studies on the mechanisms of SPCs, including the roles of genomic changes after first primary cancer (FPC) treatments, stromal cell phenotypic and metabolic changes, hormone levels and receptor expression, immunosuppression, aberrant gene methylation, EGFR signaling, and cell-free DNA in SPC development. This comprehensive analysis contributes to elucidating current research trends in SPC mechanisms and enhances our understanding of the underlying pathophysiology. Furthermore, potential applications of intratumoral microbes, single-cell multi-omics, and metabolomics in investigating SPC mechanisms are also discussed, providing new ideas for follow-up studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.